MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Becton Dickinson and Quest Diagnostics Partner on CDx Development

NextEdge Admin

26 Jul 2024

2 min 9 sec

Quest Diagnostics,flow cytometry,collaboration

Becton Dickinson (BD) announced a collaboration with Quest Diagnostics to develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx) for cancer and other diseases. The financial terms were not disclosed.

BD aims to offer pharmaceutical developers a comprehensive solution for CDx, covering exploratory panel development to the manufacture and distribution of FDA-cleared diagnostic kits. Typically, CDx for therapy selection uses methods like immunohistochemistry, fluorescence in situ hybridization, PCR, next-generation sequencing, and imaging. Flow cytometry, however, can rapidly analyze and sort individual cells, offering insights into an individual's immune response and aiding in patient management.

"This strategic collaboration with BD combines our expertise in developing and validating biomarkers and assays with BD's leadership in flow cytometry to offer a fully integrated solution on a larger scale," stated William Finger, VP and general manager of pharma services for Quest Diagnostics.

In 2023, BD launched the FACSDiscover S8 spectral flow cytometry platform and introduced three- and four-laser additions to the existing five-laser instrument earlier this year. This system enables high-speed cell sorting using both fluorescent and nonfluorescent parameters. Additionally, BD entered a collaboration with Laboratory Corporation of America in 2022 to develop flow cytometry-based CDx.

This partnership aims to enhance the capabilities of flow cytometry in CDx, providing a robust solution for pharma developers in the diagnostic landscape.